HM 01 - HelsinnAlternative Names: HM01
Latest Information Update: 12 Oct 2015
At a glance
- Originator Helsinn
- Mechanism of Action Ghrelin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Neuropathic pain
Most Recent Events
- 12 Oct 2015 Phase-I clinical trials in Neuropathic pain (chemotherapy-induced) in Europe (PO)
- 18 Nov 2014 Preclinical trials in Neuropathic pain in Europe (PO)